ESC Premium Access

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

Congress Presentation

About the speaker

Doctor Stefan Mulverstedt

Bispebjerg University Hospital, Copenhagen (Denmark)
0 follower

4 more presentations in this session

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

Speaker: Professor S. Nicholls (Melbourne, AU)


The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

Speaker: Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)


The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.

Speaker: Mrs A. Tsouka (Ioannina, GR)


Positioning PCSK9 inhibitors therapy in clinical practice.

Speaker: Professor K. Ray (London, GB)


Access the full session

PCSK9 inhibitors: from cells to patients

Speakers: Doctor S. Mulverstedt, Professor S. Nicholls, Doctor O. Itzhaki Ben Zadok, Mrs A. Tsouka, Professor K. Ray

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb